Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

PURPOSE: The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. PATIENTS AND METHODS: This phase I, nonrandomized, open-label, dose-escalation trial used a 3 + 3 dose-escalation scheme and in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Hong, David, Infante, Jeffrey, Janku, Filip, Jones, Suzanne, Nguyen, Ly M., Burris, Howard, Naing, Aung, Bauer, Todd M., Piha-Paul, Sarina, Johnson, Faye M., Kurzrock, Razelle, Golden, Lisa, Hynes, Scott, Lin, Ji, Lin, Aimee Bence, Bendell, Johanna
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2016
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321045/
https://ncbi.nlm.nih.gov/pubmed/27044938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.5788
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars